Please note
This trial is no longer recruiting patients. We hope to add results when they are available.
Lung cancer, Non small cell lung cancer (NSCLC)
Closed
Phase 3
This trial is looking at adding oleclumab or monalizumab to durvalumab for non small cell lung cancer.
It is for people whose cancer:
has spread into nearby tissues and it isn’t possible to remove with surgery (stage 3 lung cancer) and
hasn’t got worse following
Recruitment start: 7 February 2022
Recruitment end: 5 June 2025
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Grant Stewart
AstraZeneca
Last reviewed: 4 June 2025
CRUK internal database number: 18222
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
